BHR specializes in innovative diagnostic solutions for point of care Collaboration focuses on SphingoTec’s proprietary assays for bio-ADM®, penKid® and DPP3 Investigator-initiated study in COVID-19 at Guy’s & St Thomas’ Hospital and King's College Hospital NHS Trust Warwickshire, United Kingdom and Hennigsdorf, Germany, September 29, 2020 - BHR Pharmaceuticals Ltd (“BHR”) and SphingoTec GmbH (“SphingoTec”)…Read more
Recent Posts by ruxandralenz
penKid® (Proenkephalin), a unique biomarker for the real-time assessment of kidney function Novel data now demonstrate that penKid® also accurately predicts acute kidney injury in infants and provides substantial additional value on top of the diagnostic standard of care Hennigsdorf/Berlin, Germany, August 27, 2020 – Diagnostics company SphingoTec GmbH (“SphingoTec”) announced today the publication of…Read more
Hennigsdorf, Germany August 19, 2020 – Diagnostic company SphingoTec GmbH (SphingoTec) today announced that the Company has issued a non-brokered, unsecured convertible note facility amounting to EUR 5 million that was fully subscribed by current and new investors. The proceeds of the transaction will bridge to a larger financing round planned for later this year…Read more
Hennigsdorf/Berlin, Germany – August 6, 2020 – Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced that Dr Andreas Bergman, CEO, and Ferdinand Von Humboldt, CFO, will be presenting a corporate overview at the Summer Private Company Showcase, hosted by Solebury Trout on August 10, 2020. SphingoTec develops and markets in-vitro diagnostic tests for novel and proprietary…Read more
Recent Comments by ruxandralenz
No comments by ruxandralenz yet.